What is the current price of pirtobrutinib?

Pirtobrutinib is a new generation BTK inhibitor that is mainly used to treat a variety of hematological malignancies, especially patients who are resistant or ineffective to previous generation BTK inhibitors. The drug has been approved for marketing in China. However, due to its short time on the market, it is currently difficult to purchase it directly in domestic hospitals or pharmacies, and the circulation channels have not yet been fully expanded. Therefore, many patients still need to rely on overseas channels to obtain drugs.

Currently in overseas markets, the original drug of pitobrutinib is mainly produced by the American Eli Lilly and Company (Eli Lilly) and is divided into two channels: the American version and the European version. According to public information, its price is relatively expensive. Taking the common specifications of 50mg*30 tablets as an example, the US and European versions are generally priced around 100,000 yuan. The specific price will fluctuate slightly depending on the country and region, supply channels and exchange rate changes. Due to the high price, it imposes a greater financial burden on patients.

In order to alleviate this problem, some overseas countries and regions have begun to introduce generic versions of pitobrutinib. Among them, Laos Lucius Pharmaceutical Company received approval from the local Ministry of Health to launch a generic version of pitobrutinib with a specification of 50mg*30 tablets. The current price of this generic drug is less than 3,000 yuan. It has a clear price advantage over the original drug, and its ingredients and efficacy are also highly consistent with the original drug. Therefore, it has become one of the alternatives considered by many patients.

To sum up, although pitobrutinib has been launched in China, due to limited access channels, price and availability are still the focus of patients' attention. If it cannot be purchased domestically, generic drugs can be obtained through formal overseas channels as an alternative. It is recommended that patients consult a professional doctor before taking medication to confirm the indications and dosage to ensure medication safety and therapeutic effect.

Reference materials:https://go.drugbank.com/drugs/DB17472